The Journal of Natural and Integrative Pharmacotherapy (JNIP) is committed to publishing cutting-edge research and evidence-based insights in the realm of natural, herbal, and integrative medicine. Each issue showcases peer-reviewed articles from global researchers, clinicians, and scholars dedicated to improving healthcare through natural and complementary therapeutic approaches.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
Reviving Ancient Remedies: Botanical Knowledge and Medical Practices Across Cultures in the Age of Discovery
Vol.1(2); Pages:1-8. Published on July-2025
Abstract
This research paper will cover the revolutionary era in the history of medicinal botany between the time Columbus first voyaged in 1492, and the middle of the seventeenth century. It follows the changing knowledge of therapeutic plants in Europe, influenced by the rediscovery of classical Greek works, the re-evaluation of Arabic and mediaeval pharmaceutical tradition and the addition of newcomics flowers of the Americas. The article notes the transformation of textual philology to empirical botanical determination and institutionalizing botanical gardens as teaching institutions. It also looks at how well New World plant knowledge was absorbed or repelled by European medical systems, providing anWARE.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Curcumin as an adjunct to antidepressant therapies in major depression: randomized, double-blind, placebo-controlled trial
Vol.1(2); Pages:9-19. Published on August-2025
Abstract
Curcuma longa, a poly-phenolised compound with demonstrated neuroprotective, anti-inflammatory effects has the potential to safeguard depressive disorders. It was a double-blind, placebo-controlled clinical trial assessing the superiority of curcumin supplementation to a standard antidepressant treatment in adults with moderate- or severe forms of major depression disorder (MDD). One hundred and twenty participants were randomized to either a group taking 500 mg of curcumin twice a day, a group taking the placebo, and in addition, their usual selective serotonin reuptake inhibitors (SSRI) for an 8-week trial. The most important outcome was the change in Hamilton Depression Rating Scale (HAM-D) scores, Beck Depression InventoryII (BDI-II), serum inflammatory biomarkers (CRP, IL-6) were measured. The curcumin group showed a much larger decrease in HAM-D scores ( -11.3 vs -7.4, p < 0.01) and BDI-II scores ( -12.7 vs -8.5, p < 0.01), at week 8 than placebo. The amount of lowering of the inflammatory markers was stronger in the curcumin group. The evidence that the study provides substantiates the position of curcumin as a useful and safe pharmacotherapy supplement in MDD, which is worth taking into account in the context of integrative therapeutic plans.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Ashwagandha Root Extract Does not Relieve Fatigue Caused by Chemotherapy: a Randomized Trial
Vol.1(2); Pages:20-30. Published on September-2025
Abstract
The effects of chemotherapy-induced fatigue (CIF) are among the most disabling outcomes of cancer treatment that remarkably influence the quality of life and adherence to the treatments. Ashwagandha (Withania somnifera) root extract with adaptogenic effects can assist with fatigue so as well as contribute to general wellbeing. In this randomized controlled trial, standardized ashwagandha root extract (at a dose of 600 mg/day) was assessed in terms of effectiveness and security in the control of CIF in chemo-treated patients with cancerous complaints of adult age. One hundred people were randomly assigned the use of ashwagandha extract or placebo in 8-weeks, both being accompanied with regular oncologic treatment. The beta cell fatigue scale was measured with the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale, and further indicators were the quality of life and serum cortisol concentrations. The findings were that the ashwagandha group had significantly higher increase on FACIT-F scores (+9.4 vs +3.1, p < 0.001) and also exhibited significant decreases in serum cortisol levels in comparison with the placebo sugar pill. There were no serious adverse events. The evidence indicates that ashwagandha supplement could be an effective and secure integrative treatment on CIF in cancer patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Blending of Omega-3 Fatty Oils and Statin Therapy in Hyperlipidemia: A Multicentric Integrative Route
Vol.1(2); Pages:31-40. Published on October-2025
Abstract
The prevalence of hyperlipidemia still continues to be a major risk factor when it comes to cardiovascular diseases, regardless of the statin use. In this multicenter prospective interventional study, the authors intended to examine the effect of an oceanic combination of omega-3 fatty acids (2 g/day) with statin therapy in a population of patients with refractory hypertriglyceridemia. As conducted in three tertiary care facilities in Lebanon, Sweden, and Norway, 180 patients were enrolled in the study with 12 weeks of randomization into either a combination therapy group or statin-only group. The key measure was the change in proportion of serum triglycerides and secondary measures were LDL-C, HDL-C, high-sensitivity C reactive protein (hs-CRP) and adverse events pattern. Combination therapy led to 26.7 percent decrease of triglycerides, 10.8 percent in control group (p < 0.001). There were also increases in the levels of HDL-C and hs-CRP. Major safety considerations were not cited. The two findings corroborate the idea of combining omega- 3 supplementation with statin medication as an effective measure of ensuring that the lipid levels of the hyperlipidemic patients are optimized.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Randomized Double-blind Trial of Bacopa monnieri with Cognitive Training in Mild Cognitive Impairment
Vol.1(2); Pages:41-51. Published on November-2025
Abstract
MCI is a potentially progressive condition with severe consequences into the older age and in need of effective interventions on the basis of adjunctive therapies to prevent cognitive degradation. This randomized and placebo-controlled design, involving a double-blind design trial was aimed to evaluate the safety and efficacy of standardized Bacopa monnieri extract 300 mg daily combined with a structured and originally designed intense 12-week computerized cognitive endpoint aim at reducing the amnesia state in the amnestic MCI patients aged between 60-79 years. Two hundred of them were randomized into BM-Std + training versus placebo + training groups. The major outcomes were ADAS-Cog and memory composite scores. Secondary outcomes measured executive function, quality of life, biomarkers of oxidative stress (MDA) and brain derived neurotrophic factor (BDNF). Significantly improved ADAS-Cog ( p < 0.001) and memory composite (p = 0.002) were observed in BM-Std group (minus 3.5 points and minus 1.6 points respectively) compared with placebo. Analysis of biomarkers showed a decrease of MDA and increase of BDNF in the treatment arm (p < 0.05) which demonstrates a neuroprotective effect. Side effects were mild and similar among the groups and most were gastrointestinal distress. Bacopa monnieri and cognitive training was well tolerated and produced clinically meaningful cognitive improvements. Greater, longitudinal studies should be conducted to determine whether these effects are lasting and whether the outcomes could prevent further dementia occurrence.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
